NS is a multisystem developmental disease. Patients with NS tend to develop JMML. SHP2D61G promotes hyperactivation of Ras/Erk1/2 to inhibit GH-induced IGF-1 release, leading to growth retardation and NS. This evidence concerns the gene IGF1 and juvenile myelomonocytic leukemia.